American journal of translational research · 2026
Effect of calcium and vitamin D supplementation on recurrence of benign paroxysmal positional vertigo in osteoporotic patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Zhenbo, He Guibo, Chen Zhi, Jie Hongyu, Zeng Qinggan
Аннотация
OBJECTIVE: To investigate whether calcium and vitamin D supplementation can reduce the recurrence of benign paroxysmal positional vertigo (BPPV) and improve quality of life in patients with osteoporosis.
METHODS: In this retrospective study, 334 patients with primary osteoporosis and posterior semicircular canal BPPV were included and divided into three groups based on treatment: Group A (n = 103; intravenous calcium gluconate infusion [20 mL diluted in 250 mL 5% glucose per day for 15 days per course, four courses total]), Group B (n = 112; intramuscular injection of vitamin D2, 150,000 IU every 15 days for two doses, then monthly for two additional doses over 3 months), and Group C (n = 119; supplementation with both calcium and vitamin D2 using the protocols of Group A and B). Dizziness Handicap Inventory (DHI) scores, BPPV recurrence, serum calcium and vitamin D levels, bone turnover markers, adverse effects, and Short Form Health Survey (SF-36) quality-of-life scores were compared among the groups.
RESULTS: At 6 months post-treatment, DHI scores were 40.57 ± 3.67 in Group A, 41.25 ± 4.11 in Group B, and 32.63 ± 2.11 in Group C. The score in Group C was significantly lower than those in Groups A and B (P < 0.001), while Groups A and B showed comparable scores (P = 0.2991). Additionally, Group C exhibited a significantly lower BPPV recurrence rate at 12 months post-treatment (P = 0.030 vs. Group A; P = 0.021 vs. Group B) and 24 months post-treatment (P = 0.016 vs. Group A; P = 0.017 vs. Group B). Serum calcium (P < 0.001 vs. both Groups A and B) and vitamin D levels (P = 0.0191 vs. Group A; P = 0.0423 vs. Group B) were significantly higher in Group C compared with the other two groups. Moreover, Group C showed improved bone metabolism, as indicated by higher procollagen type I N-terminal propeptide (P1NP) levels (P < 0.05) and lower beta-crosslaps (β-CTX) levels (P < 0.05) than the other two groups. Quality-of-life scores were significantly improved in Group C across several domains, including physical functioning, role-physical, role-emotional, mental health, and social functioning (all P < 0.001). Notably, adverse effects were comparable among the groups (all P > 0.05, Fisher's exact test).
CONCLUSION: Combined calcium and vitamin D supplementation may reduce BPPV recurrence and improve quality of life in patients with osteoporosis.
METHODS: In this retrospective study, 334 patients with primary osteoporosis and posterior semicircular canal BPPV were included and divided into three groups based on treatment: Group A (n = 103; intravenous calcium gluconate infusion [20 mL diluted in 250 mL 5% glucose per day for 15 days per course, four courses total]), Group B (n = 112; intramuscular injection of vitamin D2, 150,000 IU every 15 days for two doses, then monthly for two additional doses over 3 months), and Group C (n = 119; supplementation with both calcium and vitamin D2 using the protocols of Group A and B). Dizziness Handicap Inventory (DHI) scores, BPPV recurrence, serum calcium and vitamin D levels, bone turnover markers, adverse effects, and Short Form Health Survey (SF-36) quality-of-life scores were compared among the groups.
RESULTS: At 6 months post-treatment, DHI scores were 40.57 ± 3.67 in Group A, 41.25 ± 4.11 in Group B, and 32.63 ± 2.11 in Group C. The score in Group C was significantly lower than those in Groups A and B (P < 0.001), while Groups A and B showed comparable scores (P = 0.2991). Additionally, Group C exhibited a significantly lower BPPV recurrence rate at 12 months post-treatment (P = 0.030 vs. Group A; P = 0.021 vs. Group B) and 24 months post-treatment (P = 0.016 vs. Group A; P = 0.017 vs. Group B). Serum calcium (P < 0.001 vs. both Groups A and B) and vitamin D levels (P = 0.0191 vs. Group A; P = 0.0423 vs. Group B) were significantly higher in Group C compared with the other two groups. Moreover, Group C showed improved bone metabolism, as indicated by higher procollagen type I N-terminal propeptide (P1NP) levels (P < 0.05) and lower beta-crosslaps (β-CTX) levels (P < 0.05) than the other two groups. Quality-of-life scores were significantly improved in Group C across several domains, including physical functioning, role-physical, role-emotional, mental health, and social functioning (all P < 0.001). Notably, adverse effects were comparable among the groups (all P > 0.05, Fisher's exact test).
CONCLUSION: Combined calcium and vitamin D supplementation may reduce BPPV recurrence and improve quality of life in patients with osteoporosis.